Chemotherapy News and Research

Latest Chemotherapy News and Research

Study finds PARP1 and EZH2 as potential therapeutic targets for small cell lung cancer

Newly discovered molecular differences between small cell lung cancer and nonsmall cell lung cancer have revealed PARP1 and EZH2 as potential therapeutic targets for patients with small cell lung cancer, according to the results of a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

7 Sep 2012

Reduced NF-κB expression linκed to postradiation oral mucosa vulnerability

The fragility of oral mucosa after radiotherapy for oral squamous cell carcinoma may be due to the inhibition of the DNA transcriptor protein nuclear factor κappa-light-chain-enhancer of activated B cells, show study findings.

6 Sep 2012

Merck, Symphogen announce worldwide license agreement for Sym004 to treat cancers

Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, a class of antibody therapeutics under investigation for the treatment or prophylaxis of serious human diseases such as cancer or infectious and autoimmune diseases, today announced that an exclusive worldwide license agreement was signed with Merck KGaA, Darmstadt, Germany, for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR).

6 Sep 2012

Chemotherapy increases risk of mild cognitive deficits in breast cancer patients

A large meta-analysis conducted by researchers at Moffitt Cancer Center has concluded that breast cancer patients treated with chemotherapy are at risk for mild cognitive deficits after treatment.

6 Sep 2012

Roundup: Cancer drug cost equity bill sitting on Calif. Gov's desk; Mass. cost-containment law could harm provider credit ratings

Out-of-pocket costs for cancer drugs can vary dramatically depending on whether the medications are administered through pill form or intravenous infusion. Newer oral drugs, which can be taken at home and often have fewer side effects than older drugs, can cost patients thousands of dollars a month, while receiving chemotherapy through an IV in an infusion center typically amounts to a standard co-payment for an office visit.

6 Sep 2012

Arsenic induces acute promyelocytic leukemia remission

Elderly patients with acute promyelocytic leukemia have a high rate of response to arsenic trioxide, say researchers who believe the drug should be a first-line treatment in this population.

5 Sep 2012

Epizyme commences EPZ-5676 Phase 1 study for MLL-r leukemia

Epizyme, Inc., a company leading the creation of a new class of personalized therapeutics for patients with genetically defined cancers, announced today that it has initiated a Phase 1 Study of EPZ-5676. EPZ-5676 is a novel small molecule inhibitor of DOT1L, a histone methyltransferase (HMT) that is critical to the development of a specific type of acute leukemia defined by rearrangement of the MLL gene (MLL-r leukemia).

5 Sep 2012

Chemotherapy increases risk for mild cognitive deficits in breast cancer patients

A large meta-analysis conducted by researchers at Moffitt Cancer Center has concluded that breast cancer patients treated with chemotherapy are at risk for mild cognitive deficits after treatment.

5 Sep 2012

New strategy for outsmarting cancer through its own social intelligence

In the face of mounting evidence that cancer cells communicate, cooperate and even engage in collective decision-making, biophysicists and cancer researchers at Rice University, Tel Aviv University and Johns Hopkins University are suggesting a new strategy for outsmarting cancer through its own social intelligence.

5 Sep 2012

Biokine, BioLineRx sign license agreement to develop and commercialize BL-8040 for AML

BioLineRx Ltd., a biopharmaceutical drug development company, announced today that it has signed an exclusive, worldwide license agreement with Biokine Therapeutics Ltd., a Clal Biotechnology Industries portfolio company, for the development and commercialization of BL-8040 (formerly BKT-140), a Phase II ready drug candidate for the treatment of acute myeloid leukemia (AML), as well as other types of hematological cancer.

4 Sep 2012

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

Pfizer Inc. announced today that the European Commission (EC) has granted marketing authorization for INLYTA (axitinib) for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of kidney cancer, after failure of prior treatment with sunitinib or a cytokine.

4 Sep 2012

Ultrastable RNA nanoparticles may help treat cancer and viral infections

A new study by University of Kentucky researchers shows promise for developing ultrastable RNA nanoparticles that may help treat cancer and viral infections by regulating cell function and binding to cancers without harming surrounding tissue.

4 Sep 2012

Scientists discover new anti-cancer and anti-metastatic molecule

A new molecule with anti-cancer and anti-metastatic properties has been discovered by teams from CNRS, CEA, the Institut Curie and Inserm, in collaboration with Australian and British researchers.

4 Sep 2012

Usefulness of liver biopsy for CALI preoperative assessment questioned

Liver biopsy is not a reliable tool for preoperative assessment of chemotherapy-associated liver injuries except for steatosis, suggest study findings published in the Archives of Surgery.

3 Sep 2012

Obesity and breast cancer recurrence: an interview with Dr. Joseph Sparano

Breast cancer recurrence is a major problem after treatment of localized breast cancer. The risk of recurrence depends on several factors including the stage of presentation and the biology of the disease.

3 Sep 2012

New drug combines photothermia and chemotherapy to help fight cancer

Spanish researchers have developed on a nanometric scale a new drug that combines photothermia and chemotherapy to help fight cancer.

3 Sep 2012

UI Hospital surgeons perform first robotic-assisted kidney transplant and sleeve gastrectomy

Surgeons at the University of Illinois Hospital & Health Sciences System are developing new treatment options for obese kidney patients.

1 Sep 2012

GenSpera plans to initiate G-202 Phase II trial in prostate cancer

GenSpera, Inc. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.

1 Sep 2012

Researchers define new treatment for potentially fatal lung disease in patients with CVID

A team of researchers at the Medical College of Wisconsin and Children's Hospital of Wisconsin Research Institute defined a new treatment for a potentially fatal lung disease in patients with a primary immunodeficiency known as common variable immunodeficiency (CVID).

1 Sep 2012

Weill Cornell Medical College receives three new research grants for translational blood cancer study

Weill Cornell Medical College has been awarded three new research grants from the Leukemia & Lymphoma Society totaling $1.8 million. The funds will support critically-needed translational research for blood cancers, accelerating promising discoveries from the laboratory to the patient's bedside.

31 Aug 2012

Chemotherapy News and Research

Latest Chemotherapy News and Research

Study finds PARP1 and EZH2 as potential therapeutic targets for small cell lung cancer

Reduced NF-κB expression linκed to postradiation oral mucosa vulnerability

Merck, Symphogen announce worldwide license agreement for Sym004 to treat cancers

Chemotherapy increases risk of mild cognitive deficits in breast cancer patients

Roundup: Cancer drug cost equity bill sitting on Calif. Gov's desk; Mass. cost-containment law could harm provider credit ratings

Arsenic induces acute promyelocytic leukemia remission

Epizyme commences EPZ-5676 Phase 1 study for MLL-r leukemia

Chemotherapy increases risk for mild cognitive deficits in breast cancer patients

New strategy for outsmarting cancer through its own social intelligence

Biokine, BioLineRx sign license agreement to develop and commercialize BL-8040 for AML

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

Ultrastable RNA nanoparticles may help treat cancer and viral infections

Scientists discover new anti-cancer and anti-metastatic molecule

Usefulness of liver biopsy for CALI preoperative assessment questioned

Obesity and breast cancer recurrence: an interview with Dr. Joseph Sparano

New drug combines photothermia and chemotherapy to help fight cancer

UI Hospital surgeons perform first robotic-assisted kidney transplant and sleeve gastrectomy

GenSpera plans to initiate G-202 Phase II trial in prostate cancer

Researchers define new treatment for potentially fatal lung disease in patients with CVID

Weill Cornell Medical College receives three new research grants for translational blood cancer study

Cancer Research - Second Edition eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in